From: Change in exhaled nitric oxide during peanut challenge is related to severity of reaction
Clinical feature | Entire cohort (n = 36) |
---|---|
Age (years) | |
 Median (min, max) | 10.2 (5.1, 17.1) |
Gender (%) | |
 Males | 22 (61) |
Previous peanut ingestion (%) | |
 Total | 28 (78) |
Previous adrenaline usage (%) | |
 Total | 1 (3) |
Other food allergy (%) | |
 Total | 7 (19) |
Household smokers (%) | |
 Total | 7 (19) |
Allergic rhinitis (%) | |
 Total | 26 (72) |
AR severity for those with AR-max = 4a | |
 Median (min, max) | 2 (1, 4) |
Eczema ever (%) | |
 Total | 29 (81) |
Eczema active treatment (%) | |
 Total | 8 (22) |
SCORAD for those with visible eczema | |
 Median (min, max) | 14.7 (6.0, 36.0) |
Asthma ever (%) | |
 Total | 15 (42) |
Current preventer (%) | |
 Total | 8 (22) |
Current reliever (%) | |
 Total | 10 (28) |
Exercise related wheeze or dry nocturnal cough (%)b | |
 Total | 16 (44) |
No allergy in challenge (%) | |
 Total | 15 (42) |
CANA in challenge (%) | |
 Total | 12 (33) |
Anaphylaxis in challenge (%) | |
 Total | 9 (25) |
Peanut SPT (mm) | |
 Median (min, max) | 5.8 (0, 10.0) |
Peanut sIgE (kU/L) | |
 Median (min, max) | 1.35 (0.01, 92.00) |
Ara h2 sIgE (kU/L) | |
 Median (min, max) | 0.85 (0.00, 70.30) |
FeNO (NIOX VEROc) (ppb) | |
 Median (min, max) | 23 (5, 97) |
Percent predicted FEV1d | |
 Median (min, max) | 102 (72, 124) |
Percent predicted FVCd | |
 Median (min, max) | 100 (70, 128) |
Percent predicted FEV1/FVCd | |
 Median (min, max) | 100 (82, 114) |